Trial Profile
A phase IIb study of MS1819 for the treatment of chronic pancreatitis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Adrulipase alfa (Primary)
- Indications Pancreatitis
- Focus Therapeutic Use
- 02 Mar 2020 According to an AzurRx BioPharma media release, the company has received 1 million Euros in 2018 CIR, which will be used to fund this study.
- 15 Sep 2015 New trial record